| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. | Officer Title: Chief Operating Officer and General Counsel | Common Stock | 83.4K | $209K | $2.50 | Jan 30, 2025 | Direct |
| Black Diamond Therapeutics, Inc. | Officer Title: Chief Operating Officer and General Counsel | Stock Option (Right to Buy) | 175K | Jan 30, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc. | Jan 30, 2025 | 2 | $0 | 4 | Jan 31, 2025 | Officer Title: Chief Operating Officer and General Counsel |
| BDTX | Black Diamond Therapeutics, Inc. | Feb 14, 2024 | 1 | $0 | 4 | Feb 15, 2024 | Officer Title: Chief Operating Officer and General Counsel |
| BDTX | Black Diamond Therapeutics, Inc. | Feb 13, 2023 | 1 | $0 | 4 | Feb 15, 2023 | Officer Title: Chief Operating Officer and General Counsel |
| BDTX | Black Diamond Therapeutics, Inc. | Feb 15, 2022 | 1 | $0 | 4 | Feb 17, 2022 | Officer Title: Chief Operating Officer and General Counsel |
| BDTX | Black Diamond Therapeutics, Inc. | May 12, 2021 | 5 | -$98.8K | 4 | May 13, 2021 | Chief Operating Officer and General Counsel |